P-gp/BCRP-IN-1(compound 19)是一种潜在的、相对安全的、口服有效的外排转运蛋白(P-gp 和 BCRP)抑制剂,通过抑制 P-gp 和 BCRP 的外排功能产生耐药性逆转,可克服紫杉醇的耐药性并提高紫杉醇的口服生物利用度。
产品编号: MS-L44752 CAS No.: 2764596-06-5 分子式: C27H25ClN4O3 分子量: 488.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

P-gp/BCRP-IN-1(compound 19)是一种潜在的、相对安全的、口服有效的外排转运蛋白(P-gp 和 BCRP)抑制剂,通过抑制 P-gp 和 BCRP 的外排功能产生耐药性逆转,可克服紫杉醇的耐药性并提高紫杉醇的口服生物利用度。

生物实验数据

生物活性 P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally effective inhibitor of efflux transporters (P-gp and BCRP) that reverses drug resistance by inhibiting the efflux functions of P-gp and BCRP, overcomes paclitaxel resistance, and improves the oral bioavailability of paclitaxel.
IC50 & Target

P-gp

 

体外研究
(In Vitro)

P-gp/BCRP-IN-1 (compound 19) (0-200 μM, 48 h) has a weak anti-proliferative activity against A549 cells, and shows low cytotoxicity to the K562, K562/A02, MDCK-II, MDCK-II-BCRP cells.
P-gp/BCRP-IN-1 (48 h) exhibits the great reversal effect of resistance to both ADM (Adriamycin) and MX (Mitoxantrone) in K562/A02 cells and MDCK-II-BCRP cells, and increases the reversal activity of ADM (0-5 μM) and MX (0-20 μM) in a concentration-dependent manner.
P-gp/BCRP-IN-1 (0-5 μM, 4 h) increases drug accumulation and prevents efflux of P-gp and BCRP.
P-gp/BCRP-IN-1 (0-5 μM, 48 h) dose not affect the expression of P-gp as well as BCRP protein.
P-gp/BCRP-IN-1 (0-200 μM, 4 h) decreases the viability of Caco-2 cells, inhibits the intestinal P-gp-mediated efflux of PTX and increases its concentration in the intestinal cells, can enhance the absorption and bioavailability.
P-gp/BCRP-IN-1 prevents intracellular accumulation of anti-neoplastic drugs by impairing the function of P-gp and BCRP.

Cell Proliferation Assay

Cell Line: A549 cells, chemo-sensitive cell lines (K562, MDCK-II), chemo-resistant cell lines (K562/A02, MDCK-II-BCRP)
Concentration: 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 μM
Incubation Time: 24, 48 h
Result: Had a weak anti-proliferative activity against A549 cells, with an IC50 of 46.28 μM, and showed low cytotoxicity to the K562, K562/A02, MDCK-II, MDCK-II-BCRP cells, with IC50 values of 72.81, 43.29, 87.69, 81.22 μM, respectively.

Cell Viability Assay

Cell Line: K562/A02 cells and MDCK-II-BCRP cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Increased the reversal activity of ADM (0-5 μM) and MX (0-20 μM) in a concentration-dependent manner, exhibited the great reversal effect of resistance to both ADM and MX in K562/A02 cells and MDCK-II-BCRP cells, with IC50 values (at 5 μM) of 2.41 and 18.43 μM, RF (reversal fold, at 5 μM) of 40.51 and 37.40, and EC50of 65.31 and 98.22 nM, respectively.

Western Blot Analysis

Cell Line: K562/A02 cells and MDCK-II-BCRP cells, K562 and MDCK-II cells.
Concentration: 0, 0.5, 1, 5 μM
Incubation Time: 48 h
Result: Did not affect the expression of P-gp as well as BCRP protein, exerted resistance reversal without affecting the expression of P-gp as well as BCRP protein, but probably by inhibiting the efflux function of P-gp and BCRP.

Cell Viability Assay

Cell Line: Caco-2 cells
Concentration: 1.25, 5, 10, 20, 30, 50, 100, 200 μM
Incubation Time: 4 h
Result: Decreased the viability of Caco-2 cells to less than 20% at concentrations of 30 and 50 μM respectively, significantly decreased the Papp (apparent permeability coefficient) value, inhibited the intestinal P-gp-mediated efflux of PTX and increased its concentration in the intestinal cells, which could eventually enhance the absorption and bioavailability of the orally administered drug.
体内研究
(In Vivo)

P-gp/BCRP-IN-1 (compound 19) (Male SD rats; 5 mg/kg PTX (IV), 20 mg/kg PTX (PO), 20 mg/kg PTX and 10 mg/kg compound 19 (PO); once) increases the bioavailability of PTX when PTX is given orally.
Pharmacokinetic Parameters of P-gp/BCRP-IN-1 in male SD rats.

PTX (5 mg/kg) PTX (20 mg/kg) PTX (20 mg/kg) with 19 (10 mg/kg)
Routemax (h) IV PO PO
AUC0-t (ng*h/mL) 1734.95 ± 244.28 610.89 ± 45.62 3131.51 ± 63.17
Cmax (ng/mL) 925.86 ± 31.39 112.09 ± 25.46 652.31 ± 41.93
Tmax (h) 0.44 ± 0.05 2.00 ± 0.03 2.51 ± 0.19
T1/2 (h) 0.12 ± 0.03 1.35 ± 0.05 1.68 ± 0.15
Vd/F (L) 5.06 ± 0.09 67.38 ± 12.54 16.04 ± 0.08
CL/F (L/h) 2.88 ± 0.14 32.74 ± 5.42 6.18 ± 0.36
F (%) 100 8.80 45.1

Animal Model: Male SD rats (n = 15, three groups)
Dosage: 5 mg/kg PTX (IV); 20 mg/kg PTX (PO); 20 mg/kg PTX with 10 mg/kg compound 19 (PO)
Administration: IV, PO, once (Pharmacokinetic Analysis)
Result: Increased the bioavailability of PTX when PTX was given orally.

化学信息

分子量 488.97
分子式 C27H25ClN4O3
CAS No. 2764596-06-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础